FDA expanded ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmln) to papillary-only bladder cancer by extrapolating earlier evidence. Vanda paused VQW-765 after its Phase 3 social-anxiety trial missed, while Vir and Gilead agreed a solid-tumor T-cell engager collaboration. The roundup covers a European recommendation for Revolution Medicines' daraxonrasib in pancreatic cancer, Osivax's OVX836 influenza-vaccine miss, and Alvotech/Advanz's AVT29 high-dose Eylea (aflibercept) biosimilar filing. Galderma's planned ZO Skin Health acquisition and OrbiMed's $3 billion in fund commitments round out the day.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →